ARTICLE | Company News
Medarex and Novo Nordisk antibody deal
January 9, 2001 8:00 AM UTC
MEDX will use its UltiMAb human antibody and T-12 preclinical development systems to develop antibodies against disease targets identified by NVO. Under the agreement, NVO will develop and market resu...